Craig-Hallum Upgrades Champions Oncology to Buy, Maintains Price Target to $6
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 12 2024
0mins
Should l Buy CSBR?
Source: Benzinga
Fastest News Alerts: Benzinga Pro offers real-time intelligence and news alerts to help traders stay informed and make winning trades in the stock market.
Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CSBR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CSBR
Wall Street analysts forecast CSBR stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 6.035
Low
12.00
Averages
12.00
High
12.00
Current: 6.035
Low
12.00
Averages
12.00
High
12.00
No data
About CSBR
Champions Oncology, Inc. is a preclinical and clinical research services provider. The Company is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs through its translational oncology solutions (TOS). This technology ranges from computational-based discovery platforms, oncology software solutions, and proprietary experimental tools such as in vivo, ex vivo and biomarker platforms. Utilizing its TumorGraft Technology Platform (the Platform), it provides select services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. It also sells Lumin Bioinformatics (Lumin), an oncology data-driven software program which contains comprehensive information derived from its research services and clinical studies. Lumin leverages a large data center coupled with analytics and artificial intelligence to provide a robust tool for computational cancer research.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Champions Oncology (CSBR) Earnings Transcript
See More
Champions Oncology Reports Record Services Revenue in Q3 2026
- Record Core Services Revenue: Champions Oncology reported a record core services revenue of $16.6 million in Q3 2026, representing a 32% increase year-over-year despite an overall revenue decline of 3%, indicating strong performance in its core business and setting the stage for sustained future growth.
- Positive Adjusted EBITDA for Third Quarter: The company achieved positive adjusted EBITDA for the third consecutive quarter, with management emphasizing their commitment to full-year revenue growth while continuing to invest in both the data platform and drug discovery subsidiary, reflecting confidence in future profitability.
- Early Momentum in Data Business: Management noted early progress in the data business with new deals closed during the quarter, anticipating recognition of six-figure data revenue in Q4, which highlights the potential and rising market demand for this new business segment.
- Strategic Investment and Cost Control: Although total sales costs rose to $8.8 million, resulting in a gross margin decline to 47%, management plans to reduce costs by bringing outsourced work in-house, ensuring long-term financial health and the effectiveness of strategic investments.
See More
Champions Oncology Reports Q3 Earnings Results
- Earnings Highlights: Champions Oncology reported a Q3 non-GAAP EPS of $0.04, with revenue at $16.6 million, reflecting a 2.4% year-over-year decline, indicating pressure in market competition.
- Operational Loss: The company recorded a GAAP loss from operations of approximately $276,000, while adjusted EBITDA stood at $574,000, suggesting room for improvement in cost management.
- Margin Improvement: Champions Oncology's margin improved to 52%, indicating progress in expanding its radiolabeling and data platform, which may lay the groundwork for future profitability.
- Market Outlook: Despite the revenue decline, signals of technological platform expansion may attract investor interest, particularly against the backdrop of ongoing innovation in the biotechnology sector.
See More
BLACKSTONE REVEALS DEAL TO PURCHASE CHAMPIONS GROUP
- Announcement of Agreement: Blackstone has announced an agreement to acquire Champions Group.
- Strategic Move: This acquisition is part of Blackstone's strategy to expand its portfolio in the sports and entertainment sector.
See More
Champions Oncology (CSBR) Earnings Transcript
See More
Key Stocks Reporting Earnings This Week: Micron, FuelCell, Carnival, and Others
Earnings Reports Schedule: This week features earnings reports from various companies, including homebuilders, apparel brands, and tech firms, with notable reports from Micron Technology and Nike.
Key Earnings Dates: Major companies reporting include Navan, Ark Restaurants, and Champions Oncology on Monday; Organigram and Duluth Holdings on Tuesday; and a heavy slate on Wednesday with Jabil, General Mills, and Micron.
Investor Focus: Investors are particularly interested in Micron's performance, with expectations of strong earnings driven by high bandwidth memory sales for AI chips.
End of Week Reports: The week will conclude with Carnival Corp and other companies like Paychex and Conagra Brands reporting before Friday's market open.
See More
Champions Oncology (CSBR) Earnings Transcript
See More
Champions Oncology Reports Record Services Revenue in Q3 2026
- Record Core Services Revenue: Champions Oncology reported a record core services revenue of $16.6 million in Q3 2026, representing a 32% increase year-over-year despite an overall revenue decline of 3%, indicating strong performance in its core business and setting the stage for sustained future growth.
- Positive Adjusted EBITDA for Third Quarter: The company achieved positive adjusted EBITDA for the third consecutive quarter, with management emphasizing their commitment to full-year revenue growth while continuing to invest in both the data platform and drug discovery subsidiary, reflecting confidence in future profitability.
- Early Momentum in Data Business: Management noted early progress in the data business with new deals closed during the quarter, anticipating recognition of six-figure data revenue in Q4, which highlights the potential and rising market demand for this new business segment.
- Strategic Investment and Cost Control: Although total sales costs rose to $8.8 million, resulting in a gross margin decline to 47%, management plans to reduce costs by bringing outsourced work in-house, ensuring long-term financial health and the effectiveness of strategic investments.
See More
Champions Oncology Reports Q3 Earnings Results
- Earnings Highlights: Champions Oncology reported a Q3 non-GAAP EPS of $0.04, with revenue at $16.6 million, reflecting a 2.4% year-over-year decline, indicating pressure in market competition.
- Operational Loss: The company recorded a GAAP loss from operations of approximately $276,000, while adjusted EBITDA stood at $574,000, suggesting room for improvement in cost management.
- Margin Improvement: Champions Oncology's margin improved to 52%, indicating progress in expanding its radiolabeling and data platform, which may lay the groundwork for future profitability.
- Market Outlook: Despite the revenue decline, signals of technological platform expansion may attract investor interest, particularly against the backdrop of ongoing innovation in the biotechnology sector.
See More
BLACKSTONE REVEALS DEAL TO PURCHASE CHAMPIONS GROUP
- Announcement of Agreement: Blackstone has announced an agreement to acquire Champions Group.
- Strategic Move: This acquisition is part of Blackstone's strategy to expand its portfolio in the sports and entertainment sector.
See More
Champions Oncology (CSBR) Earnings Transcript
See More
Key Stocks Reporting Earnings This Week: Micron, FuelCell, Carnival, and Others
Earnings Reports Schedule: This week features earnings reports from various companies, including homebuilders, apparel brands, and tech firms, with notable reports from Micron Technology and Nike.
Key Earnings Dates: Major companies reporting include Navan, Ark Restaurants, and Champions Oncology on Monday; Organigram and Duluth Holdings on Tuesday; and a heavy slate on Wednesday with Jabil, General Mills, and Micron.
Investor Focus: Investors are particularly interested in Micron's performance, with expectations of strong earnings driven by high bandwidth memory sales for AI chips.
End of Week Reports: The week will conclude with Carnival Corp and other companies like Paychex and Conagra Brands reporting before Friday's market open.
See More
